1. Total flavonoids of Broussonetia papyrifera alleviate non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signaling pathways.
- Author
-
Wang Q, Wei Y, Wang Y, Yu Z, Qin H, Zhao L, Cheng J, Shen B, Jin M, and Feng H
- Subjects
- Animals, Humans, Mice, Diet, High-Fat adverse effects, Hep G2 Cells drug effects, Lipid Metabolism drug effects, Mice, Inbred C57BL, Reactive Oxygen Species metabolism, AMP-Activated Protein Kinases drug effects, AMP-Activated Protein Kinases metabolism, Broussonetia chemistry, Flavonoids pharmacology, NF-E2-Related Factor 2 drug effects, NF-E2-Related Factor 2 metabolism, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease drug therapy, Signal Transduction drug effects, TOR Serine-Threonine Kinases drug effects, TOR Serine-Threonine Kinases metabolism
- Abstract
Backgrounds: Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases. The leaves of Broussonetia papyrifera contain a large number of flavonoids, which have a variety of biological functions., Methods: In vitro experiments, free fatty acids were used to stimulate HepG2 cells. NAFLD model was established in vivo in mice fed with high fat diet (HFD) or intraperitoneally injected with Tyloxapol (Ty). At the same time, Total flavonoids of Broussonetia papyrifera (TFBP) was used to interfere with HepG2 cells or mice., Results: The results showed that TFBP significantly decreased the lipid accumulation induced by oil acid (OA) with palmitic acid (PA) in HepG2 cells. TFBP decreased the total cholesterol (TC), the triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and increased high-density lipoprotein cholesterol (HDLC) in serum. TFBP could also effectively inhibit the generation of reactive oxygen species (ROS) and restrained the level of myeloperoxidase (MPO), and enhance the activity of superoxide dismutase (SOD) to alleviate the injury from oxidative stress in the liver. Additionally, TFBP activated nuclear factor erythroid-2-related factor 2 (Nrf2) pathway to increasing the phosphorylation of AMP-activated protein kinase (AMPK). Meanwhile, protein levels of mTORC signaling pathway were evidently restrained with the treatment of TFBP., Conclusion: Our experiments proved that TFBP has the therapeutic effect in NAFLD, and the activation of Nrf2 and AMPK signaling pathways should make sense., Competing Interests: Declaration of competing interest Qi Wang, Yunfei Wei, Yeling Wang, Ziyang Yu, Haiyan Qin, Lilei Zhao, Jiaqi Cheng, Bingyu Sheng, Meiyu Jing, Haihua Feng declare that they have no conflict of interest., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF